Development and clinical evaluation of a second-generation voice prosthesis (Provox((R))2), designed for anterograde and retrograde insertion

被引:71
|
作者
Hilgers, FJM
Ackerstaff, AH
Balm, AJM
Tan, IB
Aaronson, NK
Persson, JO
机构
[1] ANTONI VAN LEEUWENHOEK HOSP,NETHERLANDS CANC INST,DEPT PSYCHOSOCIAL RES & EPIDEMIOL,NL-1066 CX AMSTERDAM,NETHERLANDS
[2] ATOS MED,DEPT BIOMED ENGN & DEV,HORBY,SWEDEN
关键词
D O I
10.3109/00016489709114220
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Prosthetic voice restoration has considerably improved the results of vocal rehabilitation after total laryngectomy, and is presently the method of choice for many health-care providers treating laryngectomized patients. The Provox(R) voice prosthesis, developed in the Netherlands Cancer Institute, is an indwelling device that has been applied in recent years with regular success. Its retrograde replacement method, using a disposable guide wire, assures reliable, atraumatic positioning of the prosthesis in the tracheoesophageal fistula. However, the method sometimes may be uncomfortable for the patient; therefore an adapted prosthesis and new replacement equipment were developed, which enable bidirectional insertion, i.e. not only in the traditional retrograde manner through the pharynx, but especially in an anterograde manner through the stoma. This second-generation voice prosthesis (Provox(R)2) was studied in a prospective clinical trial in 44 patients (33 experienced patients, seven first-time replacements and four primary insertions). The study demonstrated that the anterograde insertion with the Provox(R)2 system was applicable in all patients, making the voice prosthesis even easier to handle than with the traditional retrograde method. A stenosis of the pharyngoesophageal segment no longer interfered with the replacement. In addition, the patients judged the new method as being favourable, reporting significantly less discomfort during the replacement procedure (paired Student's t-test: p < 0.0001). Furthermore, the adapted voice prosthesis could be removed from the tracheoesophagal fistula without excessive force (mean 7.9 N, range 6.0-14.0 N), more easily than the original Provox(R) (mean 20.9 N, range 5.5-25.0 N). It can be concluded that this second-generation indwelling voice prosthesis (Provox(R)2) seems to be a further improvement in the application of this voice rehabilitation system, not only simplifying the replacement procedure, but also diminishing the discomfort for the patient.
引用
收藏
页码:889 / 896
页数:8
相关论文
共 10 条
  • [1] Insertion of Provox®2 voice prosthesis using the anterograde technique immediately after the secondary tracheoesophageal puncture
    Ng, RWM
    Lam, P
    Wong, BYH
    JOURNAL OF LARYNGOLOGY AND OTOLOGY, 2005, 119 (12) : 988 - 990
  • [2] The development and clinical evaluation of second-generation leishmaniasis vaccines
    Duthie, Malcolm S.
    Raman, Vanitha S.
    Piazza, Franco M.
    Reed, Steven G.
    VACCINE, 2012, 30 (02) : 134 - 141
  • [3] Development and (pre-) clinical assessment of a novel surgical tool for primary and secondary tracheoesophageal puncture with immediate voice prosthesis insertion, the Provox Vega Puncture Set
    Frans J. M. Hilgers
    Kai J. Lorenz
    Heinz Maier
    Cees A. Meeuwis
    Jeroen D. F. Kerrebijn
    Vincent Vander Poorten
    Anne Sophie Vinck
    Miquel Quer
    Michiel W. M. van den Brekel
    European Archives of Oto-Rhino-Laryngology, 2013, 270 : 255 - 262
  • [4] Development and (pre-) clinical assessment of a novel surgical tool for primary and secondary tracheoesophageal puncture with immediate voice prosthesis insertion, the Provox Vega Puncture Set
    Hilgers, Frans J. M.
    Lorenz, Kai J.
    Maier, Heinz
    Meeuwis, Cees A.
    Kerrebijn, Jeroen D. F.
    Vander Poorten, Vincent
    Vinck, Anne Sophie
    Quer, Miquel
    van den Brekel, Michiel W. M.
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2013, 270 (01) : 255 - 262
  • [5] Second-Generation Jak2 Inhibitors for Advanced Prostate Cancer: Are We Ready for Clinical Development?
    Beinhoff, Paul
    Sabharwal, Lavannya
    Udhane, Vindhya
    Maranto, Cristina
    LaViolette, Peter S.
    Jacobsohn, Kenneth M.
    Tsai, Susan
    Iczkowski, Kenneth A.
    Wang, Liang
    Hall, William A.
    Dehm, Scott M.
    Kilari, Deepak
    Nevalainen, Marja T.
    CANCERS, 2021, 13 (20)
  • [6] ADOPTIVE TRANSFER OF IL13Rα2-SPECIFIC T CELLS FOR THE TREATMENT OF GLIOBLASTOMA: BUILDING ON CLINICAL ACHIEVEMENTS WITH SECOND-GENERATION CARs
    Brown, Christine
    Starr, Renate
    Aguilar, Brenda
    Chang, Brenda
    Sarkissian, Aniee
    Naranjo, Araceli
    Chang, Wen-Chung
    Jensen, Michael
    D'Apuzzo, Massimo
    Barish, Michael
    Badie, Behnam
    Forman, Stephen
    NEURO-ONCOLOGY, 2014, 16
  • [7] Prospective Clinical and Pharmacological Evaluation of the Delcath System’s Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan
    Eleonora M. de Leede
    Mark C. Burgmans
    T. Susanna Meijer
    Christian H. Martini
    Fred G. J. Tijl
    Jaap Vuyk
    Arian R. van Erkel
    Cornelis J. H. van der Velde
    Ellen Kapiteijn
    Alexander L. Vahrmeijer
    CardioVascular and Interventional Radiology, 2017, 40 : 1196 - 1205
  • [8] Prospective Clinical and Pharmacological Evaluation of the Delcath System's Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan
    de Leede, Eleonora M.
    Burgmans, Mark C.
    Meijer, T. Susanna
    Martini, Christian H.
    Tijl, Fred G. J.
    Vuyk, Jaap
    van Erkel, Arian R.
    van der Velde, Cornelis J. H.
    Kapiteijn, Ellen
    Vahrmeijer, Alexander L.
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2017, 40 (08) : 1196 - 1205
  • [9] Erratum to: Prospective Clinical and Pharmacological Evaluation of the Delcath System’s Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan
    Eleonora M. de Leede
    Mark C. Burgmans
    T. Susanna Meijer
    Christian H. Martini
    Fred G. J. Tijl
    Jaap Vuyk
    Arian R. van Erkel
    Cornelis J. H. van der Velde
    Ellen Kapiteijn
    Alexander L. Vahrmeijer
    CardioVascular and Interventional Radiology, 2017, 40 : 1966 - 1966
  • [10] Prospective Clinical and Pharmacological Evaluation of the Delcath System's Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan (vol 40, pg 1196, 2017)
    de Leede, Eleonora M.
    Burgmans, Mark C.
    Meijer, T. Susanna
    Martini, Christian H.
    Tijl, Fred G. J.
    Vuyk, Jaap
    van Erkel, Arian R.
    van der Velde, Cornelis J. H.
    Kapiteijn, Ellen
    Vahrmeijer, Alexander L.
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2017, 40 (12) : 1966 - 1966